Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

Results of Two Trials Identify Potential Initiation Dosing Regimen

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study presented today (1). Statistical significance was evidenced at all doses tested (25, 100, and 150 mg equivalent [eq.a]), when given every 4 weeks with a 150 mg eq. initiation dose. A separate 53-week non-inferiority trial(b) evaluating paliperidone palmitate using only a 50 mg eq. initiation dose, and subsequent doses of 25, 50, 75, and 100 mg eq., showed that while paliperidone palmitate reduced symptoms, non-inferiority relative to risperidone LAT was not demonstrated. Safety findings in both trials were similar to those from previously published studies of paliperidone extended-release (ER) tablets in the treatment of schizophrenia (2,3). Based on these results, an additional phase III study is being conducted to further assess the higher initiation dosing regimen of paliperidone palmitate 150 mg eq. followed by a second injection of 100 mg eq. with subsequent injections every four weeks.

Paliperidone palmitate, an investigational LAT, is a formulation of the oral antipsychotic paliperidone ER, used for the acute and maintenance treatment of schizophrenia. Because of the delivery systems used, LAT formulations may produce more consistent levels of the drug in the blood and provide healthcare professionals with reassurance that patients are receiving their medication as scheduled. The two studies add more information to the body of evidence for paliperidone palmitate in the treatment of schizophrenia.

In the 13-week trial, patients were randomly assigned to receive either paliperidone palmitate 25, 100 or 150 mg eq. injection or placebo. On day 1, all patients randomly assigned to any of the paliperi
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Scientists at NYU Langone Medical Center have ... of the process for turning adult cells into so-called ... vitamin C. Using the new technique in mice, the ... adult skin cells by more than 20-fold compared with ... and reliable, and thus should generally accelerate research aimed ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2
... New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge -- OXFORD, England, October 21, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... ACCESS PHARMACEUTICALS, INC. (OTC ... leveraging its proprietary drug-delivery platforms to develop treatments in ... it has submitted additional patent applications, covering its Cobalamin-mediated ... injectable drugs, as a result of the growing interest ...
... HONG KONG, Oct. 20 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 2A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 3A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 4A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 5A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 6A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 7A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 8A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 9Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 2China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 4China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 5China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 6China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 7China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 8
(Date:9/19/2014)... professor will study multifunctional and specialized spinal cord ... National Science Foundation grant in the amount of ... professor in the Department of Biology, OU College ... differences between the multifunctional and specialized spinal cord ... and what connections they make. Berkowitz will ...
(Date:9/18/2014)... - Washington State University researchers have developed a unique ... power waste cleanup in rural areas. , The ... an inexpensive and quick way to clean up waste ... while reducing pollution. , Professor Haluk Beyenal and ... Engineering and Architecture discuss the system in the online ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... resources at the U.S. Department of Energy,s (DOE) ... how proteins misfold to create the tissue-damaging structures ... called amyloid fibrils, are also implicated in neurodegenerative ... prion diseases like Creutzfeldt-Jacob and mad cow disease., ...
... to KATC Channel 3 in Lafayette, LA on December 17, ... around Acadiana (the mostly French region of Louisiana in the ... instead controlled-sugar cane burns. But some residents living near the ... comfort. From a distance, these fires look like an ...
... trichopoda , a sprawling shrub that grows on just a ... plant in its family and genus. It is also one ... about 200 million years ago. Now, researchers from Indiana University, ... JGI), Penn State University, and the Institute of Research for ...
Cached Biology News:A wrong molecular turn leads down the path to Type 2 diabetes 2A wrong molecular turn leads down the path to Type 2 diabetes 3A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
... The MX80 Series of positioning slides ... motor, ballscrew, leadscrew, micrometer, and manual. ... high performance, cost-effective multi-axis systems. These ... bearings, encoder resolutions down to 10 ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Biology Products: